Bulletin Board
Archived Bulletin Board
About John
Latest Ideas
Symptoms
Tests and Drugs
Weight Loss Experiment
Hyperthyroidism
Hypothyroidism
Supplement List
Medical Science
Heredity
Other Diseases
Thyroid Physiology
Deeper Studies
Nutrients and Toxics
Hair Analysis
Book Reports
Glossary
Table of Contents | |
GOLD
Rough file:
In Vivo 1989 Jul-Aug;3(4):285-93
Rhodium, iridium, copper and gold antitumor organometallic compounds
(review).
Haiduc I, Silvestru C
Babes-Bolyai University, Chemistry Department, Cluj-Napoca, Romania.
Recent results on the antitumor activity of organometallic compounds of
rhodium, iridium, copper and gold are reviewed. Coordination compounds of some
organic ligands are also briefly mentioned. The most promising seem to be copper
and gold complexes which exhibited remarkable activity against several tumor
systems.
PMID: 2519867, UI: 92135659
- The following study is intriguing because the
glycosaminoglycans (GAGs), which are characteristic of Graves'
ophthalmopathy and pretibial myxedema, are able to be stained with
gold. Since these tissues take up gold, does this indicate that a gold
deficiency might be involved in their etiology? Need to look into
this.
Thyroid 1996 Feb;6(1):41-5 |
|
Is Graves' dermopathy a generalized disorder?
Peacey SR, Flemming L, Messenger A, Weetman AP
University Department of Medicine, Clinical Sciences Centre, Northern
General Hospital, Sheffield, UK.
The pathogenesis of the extrathyroidal manifestations of Graves'
disease-ophthalmopathy and pretibial myxedema (Graves' dermopathy)-involves
fibroblast activation and increased mucin (glycosaminoglycan) production. It
is nuclear why fibroblasts are activated at these sites and evidence for
site-specific and generalized fibroblast activation is conflicting. One
previous report has demonstrated an increase in glycosaminoglycan deposition
in the forearm skin of patients with Graves' disease but without pretibial
myxedema. We have sought to confirm the existence of subclinical dermopathy
in the forearm tissue from patients with untreated (UG) and treated (TG)
Graves' disease and compared the histological changes with normal controls
(C), treated toxic nodular goiter (MNG) and Graves' dermopathy specimens (PTM),
using stains for mucin, elastin, glycosaminoglycans (GAGs), and HLA-DR
molecules. Four of 4 PTM specimens stained positive for mucin, with varying
sparse, fragmented, or dense elastin fibers. Four of 5 PTM specimens stained
heavily for GAGs using colloidal iron and 2 of 5 stained heavily using
colloidal gold. None of the patients in groups UG, TG, MNG, or the controls,
showed mucin deposition or elastin changes. Mild staining with colloidal
gold for GAGs was seen in 1 each of the UG, the TG, and MNG groups, and 4 of
8 controls. Heavy staining with colloidal iron for GAGs was seen in 1 TG
patient and 1 control, while moderate staining was found in several TG, UG,
and controls. In 2 of 4 PTM specimens the monoclonal antibody CR3/43
(against HLA-DR) stained frequent dermal fibroblast-like cells and in 2 a
lymphocytic infiltrate was seen. Only 1 of 8 UG patients had multiple CR3/43
staining cells present in the dermis: 3 of 8 TG and 1 of 8 controls had a
few CR3/43 stained cells. Overall we found no evidence of dermal mucin
deposition in the forearms of 16 patients with Graves' disease and a similar
GAG distribution to normal controls. HLA-DR expression by fibroblast-like
cells in the dermis suggests activation of these cells in the dermis of the
PTM specimens, but no evidence of widespread fibroblast activation was found
in the forearms of patients with Graves' disease.
PMID: 8777383, UI: 96265651
|